Found: 65
Select item for more details and to access through your institution.
WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2013, v. 139, n. 3, p. 457, doi. 10.1007/s00432-012-1348-2
- By:
- Publication type:
- Article
Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma.
- Published in:
- 2007
- By:
- Publication type:
- journal article
Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5 microg/body) in a patient with chronic myelomonocytic leukemia.
- Published in:
- 2007
- By:
- Publication type:
- journal article
Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms tumor gene (WT1).
- Published in:
- 2003
- By:
- Publication type:
- journal article
Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis.
- Published in:
- 2003
- By:
- Publication type:
- journal article
The lck promoter-driven expression of the Wilms tumor gene WT1 blocks intrathymic differentiation of T-lineage cells.
- Published in:
- 2003
- By:
- Publication type:
- journal article
Wilms tumor gene peptide-based immunotherapy for patients with overt Leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis.
- Published in:
- International Journal of Hematology, 2003, v. 77, n. 2, p. 56, doi. 10.1007/BF02983241
- By:
- Publication type:
- Article
WT1 Enhances Proliferation and Impedes Apoptosis in KRAS Mutant NSCLC via Targeting cMyc.
- Published in:
- Cellular Physiology & Biochemistry (Karger AG), 2015, v. 35, n. 2, p. 647, doi. 10.1159/000369726
- By:
- Publication type:
- Article
T Cell-Intrinsic Vitamin A Metabolism and Its Signaling Are Targets for Memory T Cell-Based Cancer Immunotherapy.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.935465
- By:
- Publication type:
- Article
Wilms tumour 1 peptide vaccine as a cure‐oriented post‐chemotherapy strategy for patients with acute myeloid leukaemia at high risk of relapse.
- Published in:
- British Journal of Haematology, 2018, v. 182, n. 2, p. 287, doi. 10.1111/bjh.14768
- By:
- Publication type:
- Article
Immunohistochemical detection of WT1 protein in a variety of cancer cells.
- Published in:
- Modern Pathology, 2006, v. 19, n. 6, p. 804, doi. 10.1038/modpathol.3800588
- By:
- Publication type:
- Article
An Immunocompetent Mouse Model for MLL/AF9 Leukemia Reveals the Potential of Spontaneous Cytotoxic T-Cell Response to an Antigen Expressed in Leukemia Cells.
- Published in:
- PLoS ONE, 2015, v. 10, n. 12, p. 1, doi. 10.1371/journal.pone.0144594
- By:
- Publication type:
- Article
Identification of a Novel C-Terminal Truncated WT1 Isoform with Antagonistic Effects against Major WT1 Isoforms.
- Published in:
- PLoS ONE, 2015, v. 10, n. 6, p. 1, doi. 10.1371/journal.pone.0130578
- By:
- Publication type:
- Article
Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 7, p. 2347, doi. 10.1007/s00262-023-03420-8
- By:
- Publication type:
- Article
Maintenance of WT1 expression in tumor cells is associated with a good prognosis in malignant glioma patients treated with WT1 peptide vaccine immunotherapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 1, p. 189, doi. 10.1007/s00262-021-02954-z
- By:
- Publication type:
- Article
Identification of mouse helper epitopes for WT1-specific CD4<sup>+</sup> T cells.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 11, p. 3323, doi. 10.1007/s00262-021-03003-5
- By:
- Publication type:
- Article
Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 1, p. 253, doi. 10.1007/s00262-020-02675-9
- By:
- Publication type:
- Article
A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma.
- Published in:
- Cancer Immunology, Immunotherapy, 2019, v. 68, n. 2, p. 331, doi. 10.1007/s00262-018-2274-1
- By:
- Publication type:
- Article
Two distinct effector memory cell populations of WT1 (Wilms' tumor gene 1)-specific cytotoxic T lymphocytes in acute myeloid leukemia patients.
- Published in:
- Cancer Immunology, Immunotherapy, 2015, v. 64, n. 7, p. 791, doi. 10.1007/s00262-015-1683-7
- By:
- Publication type:
- Article
Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response.
- Published in:
- Cancer Immunology, Immunotherapy, 2015, v. 64, n. 6, p. 707, doi. 10.1007/s00262-015-1674-8
- By:
- Publication type:
- Article
Functional human Th17 clones with WT1-specific helper activity.
- Published in:
- Cancer Immunology, Immunotherapy, 2013, v. 62, n. 4, p. 801, doi. 10.1007/s00262-012-1385-3
- By:
- Publication type:
- Article
WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone.
- Published in:
- Cancer Immunology, Immunotherapy, 2004, v. 53, n. 7, p. 617, doi. 10.1007/s00262-003-0498-0
- By:
- Publication type:
- Article
Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues.
- Published in:
- Cancer Immunology, Immunotherapy, 2002, v. 51, n. 11-12, p. 614, doi. 10.1007/s00262-002-0328-9
- By:
- Publication type:
- Article
Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy.
- Published in:
- Oncology Research & Treatment, 2017, v. 40, n. 11, p. 682, doi. 10.1159/000481353
- By:
- Publication type:
- Article
WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1.
- Published in:
- Cancers, 2023, v. 15, n. 2, p. 393, doi. 10.3390/cancers15020393
- By:
- Publication type:
- Article
Secondary Acute Monocytic Leukemia Occurring during the Treatment of a Testicular Germ Cell Tumor.
- Published in:
- Urologia Internationalis, 1997, v. 58, n. 4, p. 239, doi. 10.1159/000282992
- By:
- Publication type:
- Article
Prognostic significance of specific anti- WT1 IgG antibody level in plasma in patients with ovarian carcinoma.
- Published in:
- Cancer Medicine, 2014, v. 3, n. 4, p. 909, doi. 10.1002/cam4.244
- By:
- Publication type:
- Article
Regulation of Stemness in Carcinoma Cells.
- Published in:
- Stem Cells International, 2017, p. 1, doi. 10.1155/2017/7681769
- By:
- Publication type:
- Article
WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient.
- Published in:
- European Journal of Haematology, 2010, v. 85, n. 4, p. 358, doi. 10.1111/j.1600-0609.2010.01497.x
- By:
- Publication type:
- Article
Prognostic significance of Wilms tumor gene (WT1) mRNA expression in soft tissue sarcoma.
- Published in:
- Cancer (0008543X), 2006, v. 106, n. 10, p. 2233, doi. 10.1002/cncr.21861
- By:
- Publication type:
- Article
A WT1 protein-derived, naturally processed 16-mer peptide, WT1<sub>332</sub>, is a promiscuous helper peptide for induction of WT1-specific Th1-type CD4<sup>+</sup> T cells.
- Published in:
- Microbiology & Immunology, 2008, v. 52, n. 12, p. 591, doi. 10.1111/j.1348-0421.2008.00080.x
- By:
- Publication type:
- Article
Identification of a WT1 protein-derived peptide, WT1<sub>187</sub>, as a HLA-A*0206-restricted, WT1-specific CTL epitope.
- Published in:
- Microbiology & Immunology, 2008, v. 52, n. 11, p. 551, doi. 10.1111/j.1348-0421.2008.00069.x
- By:
- Publication type:
- Article
Wilms’ tumor gene WT1 17AA(–)/KTS(–) isoform induces morphological changes and promotes cell migration and invasion in vitro.
- Published in:
- Cancer Science, 2006, v. 97, n. 4, p. 259, doi. 10.1111/j.1349-7006.2006.00169.x
- By:
- Publication type:
- Article
Overexpression of the Wilms' tumor gene WT1 in primary astrocytic tumors.
- Published in:
- Cancer Science, 2004, v. 95, n. 10, p. 822, doi. 10.1111/j.1349-7006.2004.tb02188.x
- By:
- Publication type:
- Article
Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma.
- Published in:
- Cancer Science, 2004, v. 95, n. 7, p. 583, doi. 10.1111/j.1349-7006.2004.tb02490.x
- By:
- Publication type:
- Article
Overexpression of the Wilms' tumor gene WT1 in colorectal adenocarcinoma.
- Published in:
- Cancer Science, 2003, v. 94, n. 8, p. 712, doi. 10.1111/j.1349-7006.2003.tb01507.x
- By:
- Publication type:
- Article
Overexpression of the Wilms' tumor gene WT1 in primary thyroid cancer.
- Published in:
- Cancer Science, 2003, v. 94, n. 7, p. 606, doi. 10.1111/j.1349-7006.2003.tb01490.x
- By:
- Publication type:
- Article
Overexpression of the Wilms' tumor gene WT1 in head and neck squamous cell carcinoma.
- Published in:
- Cancer Science, 2003, v. 94, n. 6, p. 523, doi. 10.1111/j.1349-7006.2003.tb01477.x
- By:
- Publication type:
- Article
Overexpression of the Wilms' tumor gene WT1 in human bone and soft-tissue sarcomas.
- Published in:
- Cancer Science, 2003, v. 94, n. 3, p. 271, doi. 10.1111/j.1349-7006.2003.tb01432.x
- By:
- Publication type:
- Article
Expression of the Wilms' Tumor Gene WT1 in Solid Tumors and Its Involvement in Tumor Cell Growth.
- Published in:
- Cancer Science, 1999, v. 90, n. 2, p. 194, doi. 10.1111/j.1349-7006.1999.tb00733.x
- By:
- Publication type:
- Article
Reader-free ELISPOT assay for immuno-monitoring in peptide-based cancer vaccine immunotherapy.
- Published in:
- Biomedical Reports, 2020, v. 12, n. 5, p. 244, doi. 10.3892/br.2020.1289
- By:
- Publication type:
- Article
Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers.
- Published in:
- International Journal of Cancer, 2002, v. 100, n. 3, p. 297, doi. 10.1002/ijc.10476
- By:
- Publication type:
- Article
Effects of Concomitant Temozolomide and Radiation Therapies on WT1-specific T-cells in Malignant Glioma.
- Published in:
- Japanese Journal of Clinical Oncology, 2010, v. 40, n. 5, p. 395, doi. 10.1093/jjco/hyp196
- By:
- Publication type:
- Article
A Phase I/II Trial of a WT1 (Wilms' Tumor Gene) Peptide Vaccine in Patients with Solid Malignancy: Safety Assessment Based on the Phase I Data.
- Published in:
- Japanese Journal of Clinical Oncology, 2006, v. 36, n. 4, p. 231, doi. 10.1093/jjco/hyl005
- By:
- Publication type:
- Article
WT1 peptide‐based immunotherapy for advanced thymic epithelial malignancies.
- Published in:
- International Journal of Cancer, 2018, v. 142, n. 11, p. 2375, doi. 10.1002/ijc.31253
- By:
- Publication type:
- Article
Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide.
- Published in:
- International Journal of Cancer, 2016, v. 139, n. 6, p. 1391, doi. 10.1002/ijc.30182
- By:
- Publication type:
- Article
WT1 IgG antibody for early detection of nonsmall cell lung cancer and as its prognostic factor.
- Published in:
- International Journal of Cancer, 2009, v. 125, n. 2, p. 381, doi. 10.1002/ijc.24367
- By:
- Publication type:
- Article
Glycosylation Status of CD43 Protein Is Associated with Resistance of Leukemia Cells to CTL-Mediated Cytolysis.
- Published in:
- PLoS ONE, 2016, v. 11, n. 3, p. 1, doi. 10.1371/journal.pone.0152326
- By:
- Publication type:
- Article
Feasibility of Cancer Immunotherapy with WT1 Peptide Vaccination for Solid and Hematological Malignancies in Children.
- Published in:
- 2016
- By:
- Publication type:
- journal article
A Zbtb7a proto-oncogene as a novel target for miR-125a.
- Published in:
- Molecular Carcinogenesis, 2016, v. 55, n. 12, p. 2001, doi. 10.1002/mc.22446
- By:
- Publication type:
- Article